On Oct 23, the National Medical Products Administration (NMPA) established the Center for Information in the BioPark of the Beijing Economic-Technological Development Area (Beijing E-Town).

This marks the sixth center the NMPA has set up in Beijing E-town. They are the Center for Drug Evaluation, the Center for Food and Drug Inspection, the Center for Drug Reevaluation, the Center for Medical Device Evaluation, the Center for Administrative Matters Acceptance Service and Complaint Reporting, and the Center for Information.

As the core business departments of the NMPA, the six centers in Beijing E-Town play a significant role in promoting innovative drug and medical device research and development of enterprises in the area.

The six centers are located in the Headquarters Agglomeration Area of the BioPark. Together with the three other areas of R&D Transformation Area, Medical-Engineering Convergence Zone, and Pharmaceutical Intelligent Manufacturing Zone, the BioPark can meet the spatial needs of enterprises in various stages from research and development to pilot testing and large-scale production.

Within a 15-kilometer radius of the BioPark, there are 9 regulatory agencies, 16 top-tier hospitals, and 5 prestigious medical schools. Leveraging the strong foundation of the biopharmaceutical industry in Beijing E-Town, it provides abundant resources for pharmaceutical innovation.

Since July, the BioPark has attracted a number of multinational pharmaceutical companies, such as Lilly, Pfizer, Bayer, AstraZeneca, Medtronic, and HUYABIO.

In the future, the BioPark is expected to develop into an internationally influential hub for biopharmaceutical industry innovation, the first stop for global pharmaceutical innovation talents to start businesses in China, a demonstration area for AI-enabled applications in the national pharmaceutical and health industry, and a pilot field for national innovation and pharmaceutical policy reforms.